# Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

> **NCT01970904** · NA · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 147 (actual)

## Conditions studied

- Hepatitis C
- Liver Disease

## Interventions

- **DRUG:** Alisporivir
- **DRUG:** Ribavirin
- **DRUG:** Peg-IFNα2a

## Key facts

- **NCT ID:** NCT01970904
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970904, "Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01970904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*